Anixa Biosciences CEO buys 5,000 shares

Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock in an open-market transaction on July 31, 2026, at $3.47 per share.

Accepted by SEC EDGAR 08/03/2026 - 08:45 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock in an open-market transaction on July 31, 2026, at $3.47 per share. After this purchase, he directly holds 657,000 shares of Anixa Biosciences common stock.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 5,000 shs ($17K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$3.47	$17K

Holdings After Transaction: Common Stock — 657,000 shares (Direct)

Key Figures

Shares Purchased: 5,000 shares Purchase Price: $3.47 per share Shares Owned After: 657,000 shares +2 more

5 metrics

Shares Purchased 5,000 shares Common stock bought by Amit Kumar on 2026-07-31

Purchase Price $3.47 per share Price per share for the common stock purchase

Shares Owned After 657,000 shares Direct common stock holdings of Amit Kumar after the transaction

Transaction Code P Indicates an open-market or private purchase of non-derivative securities

Transaction Date 2026-07-31 Date of the reported common stock purchase

Key Terms

non-derivative, open market or private transaction, Rule 10b5-1, direct or indirect ownership

4 terms

non-derivative financial

"transaction_type": "non-derivative" for the common stock trade"

open market or private transaction financial

"transaction_code_description": "Purchase in open market or private transaction""

Rule 10b5-1 regulatory

"The Rule 10b5-1 trading plan checkbox (aff_10b5_one) is marked false"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

direct or indirect ownership financial

"direct_or_indirect uses D/I for Direct or Indirect ownership type"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider purchase did Anixa Biosciences (ANIX) CEO Amit Kumar make?

Amit Kumar purchased 5,000 shares of Anixa Biosciences common stock at $3.47 per share on July 31, 2026. Following this open-market transaction, his direct ownership increased to 657,000 shares of the company’s common stock.

When did the recent Anixa Biosciences (ANIX) insider transaction occur?

The reported insider purchase took place on July 31, 2026. On that date, CEO Amit Kumar acquired 5,000 shares of Anixa Biosciences common stock in an open-market transaction at a price of $3.47 per share.

How many Anixa Biosciences (ANIX) shares does Amit Kumar own after the transaction?

After the reported purchase, Amit Kumar directly owns 657,000 shares of Anixa Biosciences common stock. This reflects the addition of 5,000 shares acquired in an open-market transaction at $3.47 per share on July 31, 2026.

What was the price paid in the latest Anixa Biosciences (ANIX) insider buy?

The shares were purchased at $3.47 per share. CEO Amit Kumar acquired 5,000 shares of Anixa Biosciences common stock at this price in an open-market transaction dated July 31, 2026, increasing his direct holdings to 657,000 shares.

Was the Anixa Biosciences (ANIX) insider transaction made under a Rule 10b5-1 plan?

The Rule 10b5-1 trading plan checkbox is marked false, indicating the transaction was not affirmed as made under a Rule 10b5-1 plan. The purchase is reported as an open-market acquisition of 5,000 shares at $3.47 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		P		5,000	A	$3.47	657,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)